na(+)

DMPS-Na is an arsenicolytic agent with toxicity that can be used to study cell membranes.

NA-17 is a naphthalimide compound with antitumor activity and exhibits lower toxicity to normal cells such as HL-7702 and WI-38. It demonstrates p53-dependent inhibition selectivity in various NSCLC cells, inducing the accumulation of active p53 in the mitochondria and nuclei of these cells. NA-17 causes cell cycle arrest in the G1 phase and promotes apoptosis and cell death.

NA-1-157 is a potent irreversible covalent inhibitor that targets GES-5 carbapenemase, with a minimum inhibitory concentration (MIC) of 0.5 μg/mL.

NA-014 (40) is a selective positive modulator of EAAT2 with an EC50 value of 3 nM.

1,2-Distearoyl-sn-glycero-3-phosphatidic acid (Na+ salt) is a useful organic compound for research related to life sciences and the catalog number is T67073.

Nelonemdaz Na is a NMDA receptor antagonist potentially for the treatment of stroke.

Briciclib Na inhibits benzylstyryl sulfone kinase and is use for the treatment of Cancer

Eprociclovir Na is the salt form of Eprociclovir, also known as A-5021, a new acyclovir analogue and a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus. Eprociclovir possess potent anti-herpetic activity against most human herpesviruses. A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Eprociclovir inhibits murine herpetic keratitis. A-5021 eyedrops, which are easily applied onto the affected cornea, ameliorated clinical scores and suppressed virus growth. Eprociclovir is a promising alternative treatment of herpetic keratitis.

Obafistat Na is an aldo-keto reductase AKR1C3 inhibitor.

Idraparinux Na is an Antithrombotic, Indirect, Selective, Synthetic Factor Xa Inhibitor

NA 382 is a staurosporine derivative that inhibits multidrug resistance.

NA 0362 is a derivative of SF 2370 that inhibits smooth muscle contraction.

Deldeprevir Na is an Antiviral Polyprotein cleavage inhibitor. HCV NS3/4A inhibitor.

Kijimicin Na is the salt form of Kijimicin Free Base, a polyether antibiotic and inhibitor of human immunodeficiency virus in acutely and chronically infected cells.

NA 0346 is a derivative of SF 2370 that shows long lasting antihypertensive action as well as potent protein kinases inhibitory activity.

Diclazuril Na is a coccidiostat and GAPDH inhibitor used to prevent parasitic contamination of livestock and poultry feed.

CEF19, Epstein-Barr Virus latent NA-3A (458-466), is a peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain).

Na+-Ca2+Exchanger inhibitory peptide (XIP) is an inhibitor of the Na+-Ca2+ exchanger with a Ki of 200 nM. It acts non-competitively to inhibit Na+-dependent Ca2+ uptake and Na+-dependent Ca2+ efflux in sarcolemmal vesicles.

TAPS sodium is a biological buffer that maintains the structural integrity of lysozyme and prevents thermal denaturation at elevated temperatures. With a pKa of 8.1, TAPS facilitates achieving half-maximal activity of the connexin protein channel.

Etomoxir sodium salt ((R)-Etomoxir sodium salt) is a carnitine palmitoyltransferase 1a (CPT-1a) inhibitor that inhibits fatty acid oxidation (FAO). Etomoxir sodium salt has antitumor activity.

[Sar9,Met(O2)11]-Substance P (NA) is an NK1 receptor agonist.

2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a second messenger in cellular innate immunity, catalyzed by cGAMP synthase (cGAS) under DNA binding conditions. It binds to STING to form a dimer, inducing the production and expression of interferon-β and other cytokines.

Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity.

Suramin Sodium Salt (BAY-205) is a sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.